Retiro De Equipo (Recall) de Architect Toxo IgM Assay

Según Department of Health, Therapeutic Goods Administration, este evento ( retiro de equipo (recall) ) involucró a un dispositivo médico en Australia que fue producido por Abbott Australasia Pty Ltd Diagnostic Division.

¿Qué es esto?

Una corrección al equipo o acción de retiro tomada por el fabricante para abordar un problema con un dispositivo médico. Los retiros (recalls) ocurren cuando un dispositivo médico está defectuoso, cuando puede poner en riesgo la salud, o cuando simultáneamente está defectuoso y puede poner en riesgo la salud.

Más información acerca de la data acá
  • Tipo de evento
  • ID del evento
  • Clase de Riesgo del Evento
    Class II
  • Fecha de inicio del evento
  • País del evento
  • Fuente del evento
  • URL de la fuente del evento
  • Notas / Alertas
    Australian data is current through July 2018. All of the data comes from the Australian Therapeutic Goods Administration, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Australia.
  • Notas adicionales en la data
  • Causa
    Abbott diagnostics has identified an issue with the architect toxo igm assay where an increase in grayzone and/or false reactive results have been observed for samples from immunocompromised patients or newborns as well as cord blood samples for certain lot numbers. these sample types share the commonality of low total igm titer. internal studies with the architect toxo igm assay have shown that pregnant women samples and serum and plasma blood donor samples are not impacted and meet assay specificity claims.Assay sensitivity is not impacted. there is the potential for false reactive patient results that may be due to reduced specificity in low total igm titer samples (eg. samples from immunocompromised patients or newborns or cord blood samples).
  • Acción
    Users are advised to review the letter with their Medical Director. Additional testing with a secondary method is recommended to confirm reactive results (= 0.60 Index or = 1.00 S/CO) for samples from immunocompromised patients or newborns or cord blood samples and other samples with expected low IgM concentrations. Abbott has identified a solution to address this issue with a planned product modification expected in Q1 2017.


  • Modelo / Serial
    Architect Toxo IgM AssayList Number: 6C20-25Lot Numbers: 64245LI00 (Exp.: 12/04/2017), 66063LI00 (Exp.: 13/05/2017), 67003LI00 (Exp.: 12/05/2017), 68443LI00 (Exp.: 19/07/2017)ARTG Number: 188821
  • Manufacturer


  • Empresa matriz del fabricante (2017)
  • Comentario del fabricante
    “We are in constant communication with regulatory agencies and competent authorities worldwide which allows us to implement global recalls or in-country communication quickly and effectively,” Abbott, which now owns St. Jude Medical told ICIJ in a statement. In addition to sending global notices to physicians worldwide, we also make sure that product advisories are available online and classification of product recalls and product advisories are determined by global regulatory bodies which can impact the timing in any given country. MD companies follow varying regulations in different countries. In come countries software is not regulated so a recall in one country related to software would not be classified as a recall or field action in another. In addition, review cycles within the regulatory process can be different in each country which can impact communication and recall timing.
  • Source